We are live on ! Find out more
SCNI

Scinai Immunotherapeutics
SCNI

11 hedge funds and large institutions have $2.98M invested in Scinai Immunotherapeutics in 2018 Q2 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, 2 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

0.15% less ownership

Funds ownership: 2.58% → 2.42% (-0.15%)

21% less funds holding

Funds holding: 14 → 11 (-3)

100% less capital inflows, than outflows

Capital inflows: $0 | Capital outflows: $156K

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 3

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 2

Holders
11
Holders Change
-3
Holders Change %
-21.43%
% of All Funds
0.25%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
–
Reduced
2
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
Harel Insurance Investments & Financial Services
Harel Insurance Investments & Financial Services
Israel
-$57K
2
Renaissance Technologies
Renaissance Technologies
New York
-$55K
3
Deutsche Bank
Deutsche Bank
Germany
-$19.4K
4
DAFNA Capital Management
DAFNA Capital Management
California
-$18K
5
UBS Group
UBS Group
Switzerland
-$6.48K

SCNI Hedge Fund Activity: Q2 2018 in Review

11 of the 4,386 institutional investors tracked by Wall St. Rank reported a position in Scinai Immunotherapeutics (SCNI) for Q2 2018, worth a combined $2.98M — up 15% from $2.58M a quarter earlier.

Sellers outnumbered buyers: 3 funds closed out of SCNI and 0 opened new positions — a net loss of 3 holders — while 2 trimmed existing stakes and 0 added.

The largest seller was Harel Insurance Investments & Financial Services, exiting entirely with an estimated $57K sold.

  • 11 institutional investors held Scinai Immunotherapeutics (SCNI) as of Q2 2018, down from 14 in Q1 2018.
  • Funds reported $2.98M of Scinai Immunotherapeutics stock for Q2 2018, up 15% quarter-over-quarter.
  • 0 funds opened new Scinai Immunotherapeutics positions in Q2 2018 and 3 closed out, a net change of -3 holders.
  • The largest Scinai Immunotherapeutics seller in Q2 2018 was Harel Insurance Investments & Financial Services, an estimated $57K sold.

Based on aggregated 13F filings for Q2 2018.